Purdue Warns OxyContin Copies’ Launch Would Imperil Opioid Deal

Purdue Pharma LP predicted “enormous” harm that would jeopardize funding for its $6 billion OxyContin settlement unless a federal judge orders that Accord Healthcare Inc. provide advance notice of any regulatory approval and anticipated launch of its copies of the opioid.

District Judge Richard G. Andrews on Wednesday acknowledged the urgency of Purdue concerns and said they could be addressed in a separate order. His comments came in an oral order denying Purdue’s request to add certain language to his final judgment formalizing the Intas Pharmaceuticals Ltd. unit’s patent-suit victory last week in the US District Court for the District ...